Consensus Azenta, Inc.

Stocks

AZTA

US1143401024

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-07-02 EDT			5-day change	1st Jan Change
25.84 ^USD	-1.34%		+4.91%	-22.31%

06-28	Azenta, Inc.(NasdaqGS:AZTA) added to Russell 2000 Value-Defensive Index	CI
06-28	Azenta, Inc.(NasdaqGS:AZTA) added to Russell 2000 Defensive Index	CI

Evolution of the Average Target: Azenta, Inc.

Evolution of the Target Price: Azenta, Inc.

Changes in Analyst Recommendations: Azenta, Inc.

3c6595890493a3ec2941.02gfXavQG-eWiOEyujFduQTZ8ndKteHqd0nn83f6nCY.kj5xLMW8KNX6xIdwj2cN7361xwEehoSHJny0ikCLq3-RIisWxOJqocnc1Q~48bb7a3f5c58bf84eb913fb49121e460

Analysts' recommendations: Azenta, Inc.

05-07	Needham Cuts Price Target on Azenta to $33 From $44, Keeps Buy Rating	MT
12-19	Needham Raises Price Target on Azenta to $44 From $42, Keeps Buy Rating	MT
11-24	Needham Raises Price Target on Azenta to $42 From $40, Keeps Buy Rating	MT
25-10-30	Jefferies Upgrades Azenta to Buy From Hold, Adjusts Price Target to $38 From $30	MT
25-08-06	Raymond James Upgrades Azenta to Outperform From Market Perform	MT
25-05-07	Needham Adjusts Price Target on Azenta to $40 From $59, Keeps Buy Rating	MT
25-02-27	TD Cowen Initiates Coverage on Azenta With Hold Rating, $50 Price Target	MT
24-12-18	Stephens Upgrades Azenta to Overweight From Equal Weight, Adjusts Price Target to $60 From $50	MT
24-05-09	Needham Adjusts Price Target on Azenta to $69 From $75, Keeps Buy Rating	MT
24-04-04	Evercore ISI Raises Azenta's Price Target to $60 From $64, Maintains In Line Rating	MT
24-04-04	Jefferies Initiates Coverage on Azenta With Hold Rating, $64 Price Target	MT
24-02-08	Needham Trims Price Target on Azenta to $75 From $76, Maintains Buy Rating	MT
24-02-01	B. Riley Adjusts Azenta's Price Target to $79 From $61 Ahead of Fiscal Q1 Results Announcement, Keeps Buy Rating	MT
24-01-18	Needham Adjusts Azenta's Price Target to $76 From $68, Keeps Buy Rating	MT
23-08-09	Needham Raises Price Target on Azenta to $65 From $55, Maintains Buy Rating	MT
23-08-04	B. Riley Lowers Azenta's PT to $61 From $68 After Lower-Than-Consensus Fiscal Q3 Revenue, Keeps Buy Rating	MT
23-07-19	Raymond James Initiates Azenta With Market Perform Rating	MT
23-05-10	Needham Adjusts Price Target on Azenta to $55 From $68, Keeps Buy Rating	MT
23-05-10	KeyBanc Downgrades Azenta to Sector Weight From Overweight After Fiscal Q2 Miss, Says B-Medical 'Reduces Visibility'	MT
23-02-10	B. Riley Lowers Azenta's Price Target to $68 From $77, Keeps Buy Rating	MT
23-02-09	Needham Adjusts Price Target on Azenta to $68 From $78, Maintains Buy Rating	MT
23-02-09	Stephens Downgrades Azenta to Equalweight From Overweight, Adjusts Price Target to $60 From $65	MT
23-02-08	Needham Raises Price Target for Azenta to $78 From $74, Maintains Buy Rating	MT
23-01-03	Evercore ISI Downgrades Azenta to In Line From Outperform, Adjusts Price Target to $62 From $60	MT
22-11-15	Needham Raises Price Target on Azenta to $78 From $74, Maintains Buy Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	AZENTA, INC.					+0.04%
	LONZA GROUP AG					+18.29%
	REVOLUTION MEDICINES, INC.					+2.95%
	IQVIA HOLDINGS INC.					+11.45%
	BEONE MEDICINES AG					+41.84%
	CELLTRION, INC.					+45.57%
	ASCENDIS PHARMA A/S					+9.14%
	MEDPACE HOLDINGS, INC.					-18.41%
	EUROFINS SCIENTIFIC SE					+3.75%
	ICON PUBLIC LIMITED COMPANY					+1.86%
	Average					+11.65%
	Weighted average by Cap.					+15.91%